Figitumumab: Phase I/II data

Data from 107 patients enrolled in the Phase II portion of an open-label, international Phase I/II trial showed that 30 mg/kg IV figitumumab every 4 weeks produced 15 partial responses and 25 cases of stable disease. Median PFS and OS were 1.9 and 8.9 months, respectively. In patients with pre-treatment levels of circulating IGF-1 >110 ng/mL (n=79), median OS was 10.5 months vs. 4.5 months in patients with a baseline IGF-1 <=110 ng/mL (n=19; p<0.001). ...